Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
petiveria alliacea extract
- Development stage
- Phase 2
- Lead developer
- Pontificia Universidad Javeriana
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Petiveria alliacea extract, specifically the standardized formulations Esperanza (aqueous) and Anamu-SC (alcoholic), is a botanical drug candidate developed by the Pontificia Universidad Javeriana. It functions as a metabolic modulator or 'mitocan' by targeting tumor cell bioenergetics. The extract inhibits glycolytic flux and oxidative phosphorylation, leading to ATP depletion and increased reactive oxygen species (ROS) production, which selectively induces apoptosis in cancer cells while sparing normal cells. It also exhibits immunomodulatory properties by regulating cytokine production, including the induction of IL-10 and IFN-gamma. The extract is currently being evaluated in Phase I/II clinical trials for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, and metastatic gastrointestinal tumors, often in combination with standard chemotherapy.
- Other names
- Anamu extractGuinea Hen Weed extract
02
Targets
PKM2 (Pyruvate kinase M2 isoform)FASN (Fatty acid synthase)
Beyond the preview
Go deeper on petiveria alliacea extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on petiveria alliacea extract.